Literature DB >> 27184044

Practical Approaches to "Top-Down" Therapies for Crohn's Disease.

Aranzazu Jauregui Amezaga1, Gert Van Assche2.   

Abstract

Crohn's disease (CD) is a chronic, progressive, and disabling disease that leads in most cases to the development of bowel damage presenting as a fistula, abscess, or stricture. For years, therapy for Crohn's disease has been based on a "step-up" approach, in which anti-TNF agents are administered after the failure of steroids and immunosuppressants. However, recent studies have suggested that early introduction of anti-TNF agents combined with immunosuppressants can modify the natural history of the disease. Patients who could benefit more of this "top-down" strategy would be those at elevated risk of a complicated or severe inflammatory bowel disease or with factors that can predict an aggressive disease course. Therefore, the management of a patient with CD should be personalized, taking into account the patient's specific characteristics and comorbidities, disease activity, site and behavior of the disease, and predictable factors of poor prognosis. A balance between medication and potential adverse effects should be achieved, trying to avoid under or overtreatment, always discussing the different therapeutic options with the patient. The natural history of ulcerative colitis differs from CD and, to date, there is not much scientific evidence on the use of early combined immunosuppression.

Entities:  

Keywords:  Adalimumab; Anti-TNF; Crohn’s disease; Early combined immunosuppression; Immunosuppressants; Infliximab

Mesh:

Substances:

Year:  2016        PMID: 27184044     DOI: 10.1007/s11894-016-0507-z

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  75 in total

1.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.

Authors:  A Dignass; G Van Assche; J O Lindsay; M Lémann; J Söderholm; J F Colombel; S Danese; A D'Hoore; M Gassull; F Gomollón; D W Hommes; P Michetti; C O'Morain; T Oresland; A Windsor; E F Stange; S P L Travis
Journal:  J Crohns Colitis       Date:  2010-01-15       Impact factor: 9.071

2.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

Authors:  Geert D'Haens; Filip Baert; Gert van Assche; Philip Caenepeel; Philippe Vergauwe; Hans Tuynman; Martine De Vos; Sander van Deventer; Larry Stitt; Allan Donner; Severine Vermeire; Frank J Van De Mierop; Jean-Charles R Coche; Janneke van der Woude; Thomas Ochsenkühn; Ad A van Bodegraven; Philippe P Van Hootegem; Guy L Lambrecht; Fazia Mana; Paul Rutgeerts; Brian G Feagan; Daniel Hommes
Journal:  Lancet       Date:  2008-02-23       Impact factor: 79.321

3.  Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.

Authors:  Casper Steenholdt; Akbar Molazahi; Mark Andrew Ainsworth; Jørn Brynskov; Ole Østergaard Thomsen; Jakob Benedict Seidelin
Journal:  Scand J Gastroenterol       Date:  2012-03-01       Impact factor: 2.423

Review 4.  Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis.

Authors:  Jonathan Ariyaratnam; Venkataraman Subramanian
Journal:  Am J Gastroenterol       Date:  2014-01-14       Impact factor: 10.864

5.  Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.

Authors:  Pauliina Molander; Martti Färkkilä; Kimmo Salminen; Helena Kemppainen; Timo Blomster; Ritva Koskela; Airi Jussila; Henna Rautiainen; Markku Nissinen; Johanna Haapamäki; Perttu Arkkila; Urpo Nieminen; Juha Kuisma; Jari Punkkinen; Kaija-Leena Kolho; Harri Mustonen; Taina Sipponen
Journal:  Inflamm Bowel Dis       Date:  2014-06       Impact factor: 5.325

6.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

Review 7.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

8.  Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

Authors:  Y Bouhnik; M Lémann; J Y Mary; G Scemama; R Taï; C Matuchansky; R Modigliani; J C Rambaud
Journal:  Lancet       Date:  1996-01-27       Impact factor: 79.321

9.  Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.

Authors:  Reena Khanna; Brian Bressler; Barrett G Levesque; Guangyong Zou; Larry W Stitt; Gordon R Greenberg; Remo Panaccione; Alain Bitton; Pierre Paré; Séverine Vermeire; Geert D'Haens; Donald MacIntosh; William J Sandborn; Allan Donner; Margaret K Vandervoort; Joan C Morris; Brian G Feagan
Journal:  Lancet       Date:  2015-09-03       Impact factor: 79.321

10.  Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy.

Authors:  Cong Dai; Wei-Xin Liu; Min Jiang; Ming-Jun Sun
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

View more
  4 in total

1.  Strictureplasty versus bowel resection for the surgical management of fibrostenotic Crohn's disease: a systematic review and meta-analysis.

Authors:  Waqas T Butt; Éanna J Ryan; Michael R Boland; Eilis M McCarthy; Joseph Omorogbe; Karl Hazel; Gary A Bass; Paul C Neary; Dara O Kavanagh; Deirdre McNamara; James M O'Riordan
Journal:  Int J Colorectal Dis       Date:  2020-02-11       Impact factor: 2.571

2.  Correlation between ultrasound consolidated score and simple endoscopic score for determining the activity of Crohn's disease.

Authors:  Chang Liu; Shi-Si Ding; Kun Zhang; Lin-Na Liu; Le-Hang Guo; Li-Ping Sun; Yi-Feng Zhang; Xiao-Min Sun; Wei-Wei Ren; Chong-Ke Zhao; Xiao-Long Li; Qiao Wang; Xiao-Rong Xu; Hui-Xiong Xu
Journal:  Br J Radiol       Date:  2020-02-28       Impact factor: 3.039

3.  Integrated omics profiling of dextran sodium sulfate-induced colitic mice supplemented with Wolfberry (Lycium barbarum).

Authors:  Wanping Aw; Huijuan Jia; Weida Lyu; Shinji Fukuda; Masaru Tomita; Lila Otani; Hisanori Kato
Journal:  NPJ Sci Food       Date:  2020-03-31

Review 4.  Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn's disease?

Authors:  Jonathan Jenkin Tsui; Hien Q Huynh
Journal:  Ann Gastroenterol       Date:  2018-03-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.